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PRE-TEST OF A MARKOV MODEL TO ESTIMATE 
THE COST OF ILLNESS IN AMBULATORY 
PATIENTS: A PRELIMINARY ESTIMATE USING 
PHYSICIAN SURVEY DATA
Halberg DL
University of Arkansas for Medical Sciences, Little Rock, AR, USA
It is known that the therapeutic use of drugs is often a
major contributor to iatrogenic illness. Previous estimates
of society’s cost of drug-induced illness have been esti-
mated to be between $30.1 to $136.8 billion. Therefore,
the cause and prevention of iatrogenic illness is a topic of
great importance and interest to clinicians, educators, ad-
ministrators, and society. Unfortunately, previous studies
have had key disadvantages. First, panels for achieving
necessary probabilities have been limited in scope and
sample size. Second, previous models have not addressed
the recursive nature of health-related events. 
OBJECTIVES: This study had two objectives: 1) to test and
evaluate a questionnaire that will be used in future studies
to assess the probabilities of the various possible outcomes
of drug-related morbidity and mortality (DRMM); 2) to use
this preliminary questionnaire data to produce a cost of ill-
ness model demonstrating the ability of Markov processes
to model health economic questions. 
METHODS: The questionnaire was pre-tested on 22
physicians affiliated with UAMS health center. Of these,
11 (50%) responded to the survey. After revisions were
made to this questionnaire it was mailed to 298 ran-
domly selected physicians in the state of Arkansas. Of
these, 58 usable questionnaires were obtained. Probabili-
ties for the model were compiled based on this data. A
Markov model was constructed using TreeAge Data soft-
ware. Ten possible outcome states were identified for the
model. Monte Carlo simulation was used to establish an
expected value for the cost of illness related to DRMM. 
RESULTS: Extrapolations of the data indicate that the
cost of illness in the United States related to DRMM is
approximately $38 to $52 billion dollars.
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EVALUATION OF AN EDUCATIONAL 
INTERVENTION ON THE PERCEPTION OF 
COST-EFFECTIVE INFORMATION RELATIVE TO 
CLINICAL INFORMATION
Sarratt D, Cox ER
University of Arizona, College of Pharmacy, Tucson, AZ, USA
How clinical information is presented can affect health-
care providers’ decisions regarding pharmaceuticals. With
the advent of pharmacoeconomic information, it is not
certain how this information may be perceived relative to
clinical data. 
OBJECTIVE: The purpose of this study is to determine the
impact of a 4-week pharmacoeconomic educational inter-
vention on students’ perception of cost-effective claims rel-
ative to clinical information. 
METHODS: A pre-test/post-test design was used to evalu-
ate the impact of an educational intervention on students’
likelihood of recommending the inclusion of an agent on
formulary. Data on the same product were presented using
four different methods: relative (RR) and absolute risk
(AR) reduction, number needed to treat (NNT) and cost-
effectiveness (CE) ratio. The four methods were presented
as four different therapies. Three scenarios were presented.
Students were questioned regarding their knowledge of
and confidence in interpreting cost-effective data as well as
the importance of clinical, safety, CE and cost data in eval-
uating drug therapy. 
RESULTS: Forty-nine third-year PharmD students com-
pleted both pre- and post-tests. How CE claims were per-
ceived relative to clinical information varied across each
of the three scenarios. CE ratio information was ranked
first, second and fourth in terms of the likelihood of rec-
ommending therapy across the three scenarios relative to
clinical data. In two of the three scenarios CE claims
were rated most similar to RR. Significant increases in
knowledge of and confidence in interpreting cost-effec-
tive claims were found (p  0.006). 
CONCLUSION: While overall, students perceive the
value of CE information third in importance to clinical
effectiveness and safety information, the presentation of
CE information does favorably influence the likelihood
of recommending therapy above clinical information.
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Development of the patient’s treatment record is one of the
urgent problems of the current standardization system. The
draft patient’s treatment record has been already drawn up.
Each record has been assumed to be based on a certain pa-
tient’s model—nosological, syndromal, or situation. The
latter are based respectively on a disease, syndrome, or clin-
ical situation. The patient’s model considers the phase and
stage of a disease (or an independent syndrome) and
complications. Additionally are included the terms of the
medical aid (at the outpatient clinic, in hospital, during
transportation) and its purpose (prophylaxis, diagnostics,
treatment, rehabilitation). The model specifies the range of
the simple medical services, manipulations, investigations,
procedures, groups of medical preparations to be pre-
scribed (performed) obligatory when rendering the aid in
the given situation. The model also specifies the auxiliary
range of the investigations, therapeutic manipulations, and
groups of the medicinal preparations. Development of the
